Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $36.65 USD
Change Today -0.91 / -2.42%
Volume 1.3M
MYGN On Other Exchanges
As of 4:30 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Peter D. Meldrum Ph.D.

AgeTotal Calculated CompensationThis person is connected to 56 board members in 4 different organizations across 9 different industries.

See Board Relationships
As of Fiscal Year 2014


Dr. Peter D. Meldrum, Ph.D., is a Co-Founder of Myriad Genetics Inc. and has been its Consultant since June 30, 2015. Dr. Meldrum served as the President and Chief Executive Officer of Myriad Genetics from November 1991 to June 30, 2015. Dr. Meldrum served as the Secretary and Chairman of the Board of Directors of Golden Pine Ventures, LLC. He was the Founder of Pique Therapeutics, Inc., Kylin Therapeutics, Inc. and Rosetta Inpharmatics LLC. He was involved in the founding ...

Read Full Background

Corporate Headquarters*

320 Wakara Way
Salt Lake City, Utah 84108

United States

Phone: 801-584-3600
Fax: 801-584-3640

Board Members Memberships*

Director and Member of Executive Committee
Secretary and Chairman of the Board of Directors
Independent Director and Chairman of Compensation Committee


Honorary Doctorate 2009
The University of Utah
BS 1970
The University of Utah
MBA 1974
The University of Utah
Honorary Doctorate 2004
Westminster College

Other Affiliations*

Annual Compensation*

Total Annual Compensation$996,976

Stock Options*

All Other Compensation$10,231
Exercised Options320,724
Exercised Options Value$4,690,193
Exercisable Options1,840,868
Exercisable Options Value$34,050,619
Unexercisable Options1,335,000
Unexercisable Options Value$19,015,730
Total Value of Options$57,756,541
Total Number of Options3,496,592

Total Compensation*

Total Annual Cash Compensation$2,300,707
Total Short Term Compensation$996,976
Other Long Term Compensation$10,231
Total Calculated Compensation$8,142,067
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYGN:US $36.65 USD -0.91


Joseph A. Chlapaty Chairman, Chief Executive Officer, President and Chairman of Executive Committee
Advanced Drainage Systems, Inc.
Howard G. Berger M.D.Chairman, Chief Executive Officer, President and Treasurer
RadNet, Inc.
Percy C. Tomlinson Jr.Chief Executive Officer, President and Director
Alliance Healthcare Services, Inc.
Kimberly J. Popovits Chairman, Chief Executive Officer, President and Member of Non-Management Stock Option Committee
Genomic Health Inc.
Michael J. Pellini M.D., MBAChief Executive Officer and Director
Foundation Medicine, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYRIAD GENETICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at